Requests that the FDA declare that the drug product Buspirone Tablets, 20 mg, is suitable for consideration in an Abbreviated New Drug Application (“ANDA”).
🏛 Food and Drug Administration (FDA)FDA-2026-P-2302
Documents
3
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Mar 5, 2026No comment period
- Supporting & Related Material· Mar 5, 2026